Melissa Epperly Sells 41,861 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 41,861 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the sale, the director directly owned 15,804 shares in the company, valued at $453,258.72. This trade represents a 72.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV traded down $0.50 during midday trading on Wednesday, reaching $27.80. The company had a trading volume of 4,345,944 shares, compared to its average volume of 6,400,057. The company has a fifty day simple moving average of $25.57 and a two-hundred day simple moving average of $20.99. The firm has a market cap of $19.90 billion, a price-to-earnings ratio of -23.76 and a beta of 1.17. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $30.33.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently made changes to their positions in ROIV. Jones Financial Companies Lllp boosted its holdings in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after purchasing an additional 1,148 shares during the period. SBI Securities Co. Ltd. increased its stake in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP lifted its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the period. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the 4th quarter valued at $47,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on ROIV shares. Guggenheim raised their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. HC Wainwright raised their price objective on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. The Goldman Sachs Group lifted their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and an average target price of $28.81.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.